Journal
ONCOIMMUNOLOGY
Volume 5, Issue 8, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2016.1196311
Keywords
Cancer immunity; cancer vaccines; Dendritic cell vaccine; glioma; HSPPC-96; Immunosuppression; pediatric glioma; Rindopepimut
Categories
Funding
- PHS [P50CA097257, R01CA159467, R00NS082381]
- NIH/NCI
- NIH/NINDS [R01NS080619]
- NIH/NINDS, US. Department of Health and Human Services
- Robert H. Lurie Comprehensive Cancer Center - Zell Scholar Program of the Zell Family Foundation Gift
- Northwestern Brain Tumor Institute
Ask authors/readers for more resources
The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13R alpha 2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available